Trump Plans to Fire FDA Commissioner Makary Over Policy Disputes
President Trump intends to dismiss FDA Commissioner Dr. Marty Makary despite his support for Make America Healthy Again over conflicts on vaping, abortion pills.
President Trump plans to fire FDA Commissioner Dr. Marty Makary, despite the physician's support for the administration's Make America Healthy Again movement, according to sources familiar with the decision.
Insider Wire
Sign in or create a free account.
Gain access to limited free articles, news alerts, and morning briefings.
Dr. Makary has drawn criticism within the Trump administration over his handling of three contentious policy areas: vaping regulations, abortion pill access, and his rejection of new drug approvals. The disputes have created enough friction to prompt Trump to seek new leadership at the federal health agency.
Policy Conflicts Drive Decision
The commissioner's stance on vaping policy has particularly angered administration allies who expected a more industry-friendly approach from someone aligned with the Make America Healthy Again agenda. Makary has also faced internal pushback over his decisions regarding the abortion pill mifepristone and his agency's rejection of certain pharmaceutical applications.
The planned firing represents a notable shift for an administration that initially welcomed Makary's support for reforming America's health system. The Johns Hopkins surgeon and health policy expert had positioned himself as an ally of Robert F. Kennedy Jr.'s health reform movement, which Trump embraced during the campaign.
Sources indicate that Makary's approach to drug approvals has frustrated pharmaceutical industry stakeholders and some within the administration who expected faster approvals for certain medications. His rejections of new drug applications have been viewed as overly cautious by critics seeking a more streamlined approval process.
Administration Seeks New Direction
The decision to remove Makary signals Trump's willingness to prioritize policy alignment over ideological support when it comes to key regulatory positions. The FDA commissioner role carries enormous influence over drug approvals, medical device regulations, and public health policy affecting millions of Americans.
Trump's dissatisfaction with Makary reflects broader tensions within the administration over how aggressively to pursue deregulation in the health sector while maintaining the Make America Healthy Again messaging that resonated with voters.
The timing of Makary's expected dismissal remains unclear, but administration sources suggest the decision has been made. Trump typically announces such personnel changes through social media or public statements rather than traditional channels.
The search for Makary's replacement will likely focus on candidates who can balance the administration's deregulatory goals with its health reform agenda while avoiding the policy conflicts that led to the current commissioner's downfall.
